Single-arm Phase II study evaluating the combination of mogamulizumab (MOGA) added on top of standard of care dose adjusted EPOCH (DA-EPOCH) or CHOEP in patients with newly diagnosed or relapsed/refractory (for CTCL only) aggressive T-cell lymphoma including patients wi...
- Lymphoma, T-Cell
- Recurrence
- Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
- Lymphoma, T-Cell, Cutaneous
Age: 18 years - 66+
Gender: All